With the IND approval from the FDA, we dosed our first patient in the US today in our Phase I/IIa study, NAPISTAR 1-01. Entering the clinic with our first candidate from our growing pipeline of next-generation #ADCs marks an important milestone for Tubulis and we look forward to bringing the true value of ADCs to patients with solid tumors. The first-in-human trial is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TUB-040, one of our lead candidates, as a monotherapy in patients with platinum-resistant, high-grade #OvarianCancer (PROC) or relapsed/refractory adenocarcinoma non-small cell lung cancer (#NSCLC), who have exhausted all other available treatment options. TUB-040 is a topoisomerase-I-based ADC targeting NaPi2b, which showed superior biophysical properties in preclinical studies indicating a high potential to improve efficient long-term anti-tumor responses. Find the full press release here: https://bit.ly/3Xydc3K. If you want to read more on our proprietary suite of platform technologies and vision to usher in a new ADC era for better patient outcomes at www.tubulis.com
What an achievement by the whole team! So proud to be part of it!
Congratulations on this outstanding achievement!
Having accompanied your entrepreneurial journey since 2020, we are particularly excited about this important step from a preclinical to a clinical stage company. Congratulations to the entire Tubulis team!
Congrats to the Tubulis team, dosing the first patient is always in important step forward. All the best in your trial.
Congrats, exciting news. Keeping the fingers crossed that TUB-040 will make its way through the clinic.
Congratulations to the entire @tubulis team on reaching this important milestone!
Super Proud you picked Alira Health as your CRO! Andiamo!
congratulations to the entire Tubulis GmbH team on this milestone
Excellent news and fingers crossed, Tubulis! 👍🏻👍🏻
Congratulations on this milestone! We’re proud to be part of your journey!